(Q36296415)

13 August 2017

1 reference

title

Cdk inhibitory nucleoside analogs prevent transcription from viral genomes (English)

1 reference

13 August 2017

L M Schang

1

1 reference

PubMed ID

16248044

13 August 2017

E Coccaro

series ordinal

2

1 reference

PubMed ID

16248044

13 August 2017

J J Lacasse

series ordinal

3

1 reference

13 August 2017

1 January 2005

1 reference

Nucleosides, Nucleotides & Nucleic Acids

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

5-7

1 reference

13 August 2017

829-837

1 reference

Can sequencing shed light on cell cycling?

13 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cyclin-dependent kinases as cellular targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

CDK inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Inhibition of cyclin-dependent kinases by purine analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Inhibition of DNA synthesis in human gliomas by roscovitine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

The use of herbs as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Anastrozole versus progestins/tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

A uniform procedure for the purification of CDK7/CycH/MAT1, CDK8/CycC and CDK9/CycT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

Human cytomegalovirus infection results in altered Cdk2 subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200060314

21 January 2018

Identifiers

DOI

10.1081/NCN-200060314

1 reference

13 August 2017

1 reference

PubMed ID

16248044